ATAI
achieved and expected milestones key achievements to date phase results phase results initiation of clinical programs phase results phase a results phase results phase results phase results phase results phase a results phase first subject dosed phase results anorexia efficacy study results efficacy study first subject dosed in cash as of plus access to up to an additional from term loan facility provides runway expected into we expect deliver several meaningful anticipated across our through with | ATAI
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
6 of 33
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
April 2023
achieved and expected milestones key achievements to date phase data phase data phase first subject dosed phase data phase a data phase data phase data phase data phase data phase data summer phase study data in cash as of plus access to up to an additional from term loan facility provides expected runway into we expect deliver several meaningful anticipated across our programs through with | ATAI
Investor Presentation
March 2023
achieved and expected milestones phase data phase data phase first subject dosed phase data anorexia key achievements to date phase data phase data initiation of clinical programs phase data phase a data phase data phase data phase data summer phase study data in cash as of plus access to up to an additional from term loan facility provides runway expected into we expect deliver several meaningful anticipated across our through with | ATAI
Investor Presentation
January 2023
achieved and expected milestones key achievements to date phase results phase results initiation of clinical programs phase results phase a results phase results phase results phase results phase results phase a results phase first subject dosed phase results anorexia efficacy study results efficacy study first subject dosed in cash as of plus access to up to an additional from term loan facility provides runway expected into we expect deliver several meaningful anticipated across our through with | ATAI
Investor Presentation
October 2022
achieved and expected catalysts phase results phase a results phase results phase results phase results phase results phase results phase results phase initiation phase a results phase study initiation study results phase a initiation phase initiation phase a results phase initiation study initiation in cash as of june plus access to up to from term loan facility provides runway into we will build on recent success by delivering several meaningful anticipated across our key programs through with | ATAI
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
Ocuphire Pharma
Results
March 2021
primary of subjects study eye returning to at min | Ocuphire Pharma
Ocuphire Pharma
Investor Presentation
November 2021
efficacy of subjects letter gain across | Ocuphire Pharma
Dare Bioscience
Investor Presentation
February 2023
cream phase and phase a study results parameter | Dare Bioscience
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io